Share Price and Basic Stock Data
Last Updated: December 11, 2025, 10:43 pm
| PEG Ratio | 0.00 |
|---|
Last Updated on: 11 December, 2025
Stock Ticker - BSE: 506365 | NSE: CHEMOPH
Chemo Pharma Laboratories Ltd: Intrinsic Value & Share Price Analysis
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Chemo Pharma Laboratories Ltd operates in the pharmaceuticals sector, yet its revenue trends paint a rather concerning picture. Over the past several reporting periods, the company has consistently reported zero sales since at least March 2022. This persistent absence of revenue raises questions about its operational viability and market strategy. With a current market capitalization of ₹15.9 Cr, the company’s ability to generate income is crucial for attracting investor interest. The lack of revenue is particularly alarming when considering that competitors in the pharmaceutical industry often showcase steady growth and robust sales figures. Chemo Pharma’s stagnant sales could suggest deeper issues, potentially related to product development, regulatory challenges, or market penetration strategies, all of which warrant scrutiny from prospective investors.
Profitability and Efficiency Metrics
The profitability metrics for Chemo Pharma further illustrate its struggles. The company has recorded negative net profits for multiple quarters, with the most recent figures showing a net profit of ₹-12 Cr. This translates to a return on equity (ROE) of just 3.47%, alongside a return on capital employed (ROCE) of 5.17%. Such low returns indicate that the company is not efficiently utilizing its equity base or capital. Furthermore, the operating profit margin (OPM) figures remain elusive, reflecting ongoing operational inefficiencies. While Chemo Pharma has managed to generate some other income, it has not been substantial enough to offset its operating losses. This combination of negative profitability and low operational efficiency raises red flags for investors, suggesting that a turnaround strategy is urgently needed.
Balance Sheet Strength and Financial Ratios
On the balance sheet front, Chemo Pharma presents a mixed picture. The company boasts reserves of ₹12 Cr and has maintained a zero-borrowing status, indicating a conservative approach to leveraging. This absence of debt could be perceived as a strength, suggesting that the company is not overburdened by financial obligations. However, it also raises concerns about its growth potential, as companies typically leverage debt to finance expansion or innovation. The price-to-book value ratio stands at a low 0.72x, which may attract value investors looking for undervalued stocks. Yet, the lack of growth in both assets and sales can make this valuation appear stretched. Financial ratios like the interest coverage ratio are not applicable here due to the absence of interest expenses, but the company’s overall financial health still requires careful consideration.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Chemo Pharma Laboratories reveals a significant public stake, with 71.75% of shares held by retail investors, while promoters hold 27.89%. This distribution suggests a relatively high level of public investment, which could indicate trust or interest in the company’s potential. However, the low participation from institutional investors (DIIs at 0.17% and no foreign institutional investors) raises concerns about broader market confidence in the stock. Such limited institutional backing often translates to volatility in the stock price, as retail investors can be swayed by market sentiment more easily than institutions. The number of shareholders has fluctuated slightly, standing at 6,409, which could reflect a lack of sustained interest or confidence, especially given the company’s ongoing operational challenges.
Outlook, Risks, and Final Insight
Looking ahead, Chemo Pharma Laboratories faces significant challenges that could impact its future performance. The persistent lack of revenue generation is a critical risk that could deter potential investors. Without a clear strategy for product development or market entry, the company’s future remains uncertain. Additionally, the low profitability metrics and operational inefficiencies could further complicate efforts to attract investment. On the other hand, the absence of debt provides a buffer that could be leveraged for future growth initiatives. Investors might consider the company’s potential for a turnaround, but this hinges on management’s ability to address fundamental operational issues. In summary, while Chemo Pharma has some strengths, the risks associated with its stagnant revenue and profitability metrics cannot be overlooked, making it a stock that requires cautious consideration for any investor’s portfolio.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Chemo Pharma Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 141 Cr. | 112 | 239/84.3 | 31.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,246 Cr. | 390 | 479/192 | 87.9 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.0 Cr. | 44.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 43.8 Cr. | 29.9 | 31.0/17.0 | 104 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,461.38 Cr | 1,157.79 | 51.81 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.18 | 0.12 | 0.05 | 0.02 | 0.02 | 0.05 | 0.02 | 0.02 | 0.10 | 0.05 | 0.02 | 0.02 | 0.02 |
| Operating Profit | -0.18 | -0.12 | -0.05 | -0.02 | -0.02 | -0.05 | -0.02 | -0.02 | -0.10 | -0.05 | -0.02 | -0.02 | -0.02 |
| OPM % | |||||||||||||
| Other Income | 0.13 | -0.38 | 0.59 | 0.19 | -0.10 | 0.43 | 0.46 | 0.70 | 0.25 | 0.30 | 0.63 | -0.15 | -0.16 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.05 | -0.50 | 0.54 | 0.17 | -0.12 | 0.38 | 0.44 | 0.68 | 0.15 | 0.25 | 0.61 | -0.17 | -0.18 |
| Tax % | -400.00% | 0.00% | 0.00% | 0.00% | 25.00% | 0.00% | 0.00% | 0.00% | 293.33% | 0.00% | 0.00% | 0.00% | 88.89% |
| Net Profit | 0.14 | -0.50 | 0.53 | 0.16 | -0.15 | 0.38 | 0.44 | 0.68 | -0.29 | 0.25 | 0.61 | -0.17 | -0.34 |
| EPS in Rs | 0.93 | -3.33 | 3.53 | 1.07 | -1.00 | 2.53 | 2.93 | 4.53 | -1.93 | 1.67 | 4.07 | -1.13 | -2.27 |
Last Updated: May 31, 2025, 6:32 am
Below is a detailed analysis of the quarterly data for Chemo Pharma Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
- For Expenses, as of Mar 2025, the value is 0.02 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.02 Cr..
- For Operating Profit, as of Mar 2025, the value is -0.02 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded -0.02 Cr..
- For OPM %, as of Mar 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00%.
- For Other Income, as of Mar 2025, the value is -0.16 Cr.. The value appears to be declining and may need further review. It has decreased from -0.15 Cr. (Dec 2024) to -0.16 Cr., marking a decrease of 0.01 Cr..
- For Interest, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
- For Depreciation, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
- For Profit before tax, as of Mar 2025, the value is -0.18 Cr.. The value appears to be declining and may need further review. It has decreased from -0.17 Cr. (Dec 2024) to -0.18 Cr., marking a decrease of 0.01 Cr..
- For Tax %, as of Mar 2025, the value is 88.89%. The value appears to be increasing, which may not be favorable. It has increased from 0.00% (Dec 2024) to 88.89%, marking an increase of 88.89%.
- For Net Profit, as of Mar 2025, the value is -0.34 Cr.. The value appears to be declining and may need further review. It has decreased from -0.17 Cr. (Dec 2024) to -0.34 Cr., marking a decrease of 0.17 Cr..
- For EPS in Rs, as of Mar 2025, the value is -2.27. The value appears to be declining and may need further review. It has decreased from -1.13 (Dec 2024) to -2.27, marking a decrease of 1.14.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:39 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 12 |
| Operating Profit | -0 | -0 | -0 | -0 | -0 | -1 | -0 | -0 | -0 | -0 | -0 | -0 | -12 |
| OPM % | |||||||||||||
| Other Income | 0 | 0 | 0 | 6 | 1 | 1 | 1 | 1 | 1 | 0 | 2 | 1 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | -12 |
| Tax % | 19% | 26% | 31% | 12% | 86% | 19% | 16% | 19% | -56% | 38% | 27% | 33% | |
| Net Profit | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | -12 |
| EPS in Rs | 1.60 | 1.87 | 1.47 | 31.20 | 0.67 | 1.40 | 2.80 | 1.67 | 3.73 | 0.33 | 8.00 | 2.27 | -78.06 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2022-2023 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | -100.00% | -100.00% | -100.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% |
Chemo Pharma Laboratories Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 3 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -4% |
| 3 Years: | -4% |
| TTM: | -1184% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 64% |
| 3 Years: | 54% |
| 1 Year: | 65% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 4% |
| 3 Years: | 4% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 2:56 pm
Balance Sheet
Last Updated: December 10, 2025, 4:03 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Reserves | 3 | 4 | 4 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 11 | 12 | -0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Total Liabilities | 5 | 6 | 6 | 11 | 10 | 10 | 11 | 11 | 12 | 12 | 13 | 13 | 2 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 4 | 0 | 0 |
| Other Assets | 4 | 4 | 4 | 11 | 10 | 10 | 11 | 11 | 9 | 9 | 9 | 13 | 2 |
| Total Assets | 5 | 6 | 6 | 11 | 10 | 10 | 11 | 11 | 12 | 12 | 13 | 13 | 2 |
Below is a detailed analysis of the balance sheet data for Chemo Pharma Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For Reserves, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 12.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 12.00 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. However, Reserves are negative, which is a major warning sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.00 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2.00 Cr.. The value appears to be improving (decreasing). It has decreased from 13.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 11.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 13.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 11.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 13.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 11.00 Cr..
Reserves and Borrowings are well balanced.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | ||||||||||||
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | ||||||||||||
| Working Capital Days | ||||||||||||
| ROCE % | 7% | 8% | 6% | 4% | 8% | 3% | 5% | 3% | 1% | 1% | 13% | 5% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 16 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | -9.66 |
| Diluted EPS (Rs.) | -9.66 |
| Cash EPS (Rs.) | -9.66 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 24.49 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 24.49 |
| PBDIT / Share (Rs.) | -8.98 |
| PBIT / Share (Rs.) | -8.98 |
| PBT / Share (Rs.) | -8.98 |
| Net Profit / Share (Rs.) | -9.66 |
| NP After MI And SOA / Share (Rs.) | -9.66 |
| Return on Networth / Equity (%) | -39.44 |
| Return on Capital Employeed (%) | -35.51 |
| Return On Assets (%) | -37.44 |
| Current Ratio (X) | 28.82 |
| Quick Ratio (X) | 28.82 |
| Enterprise Value (Cr.) | 2.24 |
| EV / EBITDA (X) | -1.66 |
| Price / BV (X) | 0.72 |
| EarningsYield | -0.54 |
After reviewing the key financial ratios for Chemo Pharma Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 16, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 3. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 16, the value is 24.49. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 16, the value is 24.49. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 16, the value is -8.98. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 16, the value is -8.98. This value is below the healthy minimum of 0. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 16, the value is -8.98. This value is below the healthy minimum of 0. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 16, the value is -39.44. This value is below the healthy minimum of 15. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 16, the value is -35.51. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 16, the value is -37.44. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 16, the value is 28.82. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 16, the value is 28.82. This value exceeds the healthy maximum of 2. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 16, the value is 2.24. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 16, the value is -1.66. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 16, the value is 0.72. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For EarningsYield, as of Mar 16, the value is -0.54. This value is below the healthy minimum of 5. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chemo Pharma Laboratories Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -35.51% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -39.44% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 28.82
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 51.81)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
Chemo Pharma Laboratories Ltd. is a Public Limited Listed company incorporated on 17/08/1942 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L99999MH1942PLC003556 and registration number is 003556. Currently company belongs to the Industry of Pharmaceuticals. Company's Total Operating Revenue is Rs. 0.00 Cr. and Equity Capital is Rs. 1.50 Cr. for the Year ended 31/03/2024.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 5, Kumud Apartment CHS Ltd., Thane District Maharashtra 421301 | chemopharmalab@gmail.com http://www.thechemopharmalaboratoriesltd.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Bhavin Sheth | Executive Director & CEO |
| Mr. Ashok Somani | Executive Director & CFO |
| Mrs. Shanta Somani | Non Executive Director |
| Mr. Mathura Prasad Sharma | Independent Director |
| Mr. Toby Antony | Independent Director |
| Mr. Nandkumar Pareek | Independent Director |
FAQ
What is the intrinsic value of Chemo Pharma Laboratories Ltd?
Chemo Pharma Laboratories Ltd's intrinsic value (as of 11 December 2025) is 4.08 which is 96.22% lower the current market price of 108.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 16.2 Cr. market cap, FY2025-2026 high/low of 152/63.0, reserves of ₹-0 Cr, and liabilities of 2 Cr.
What is the Market Cap of Chemo Pharma Laboratories Ltd?
The Market Cap of Chemo Pharma Laboratories Ltd is 16.2 Cr..
What is the current Stock Price of Chemo Pharma Laboratories Ltd as on 11 December 2025?
The current stock price of Chemo Pharma Laboratories Ltd as on 11 December 2025 is 108.
What is the High / Low of Chemo Pharma Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Chemo Pharma Laboratories Ltd stocks is 152/63.0.
What is the Stock P/E of Chemo Pharma Laboratories Ltd?
The Stock P/E of Chemo Pharma Laboratories Ltd is .
What is the Book Value of Chemo Pharma Laboratories Ltd?
The Book Value of Chemo Pharma Laboratories Ltd is 9.60.
What is the Dividend Yield of Chemo Pharma Laboratories Ltd?
The Dividend Yield of Chemo Pharma Laboratories Ltd is 0.00 %.
What is the ROCE of Chemo Pharma Laboratories Ltd?
The ROCE of Chemo Pharma Laboratories Ltd is 5.17 %.
What is the ROE of Chemo Pharma Laboratories Ltd?
The ROE of Chemo Pharma Laboratories Ltd is 3.47 %.
What is the Face Value of Chemo Pharma Laboratories Ltd?
The Face Value of Chemo Pharma Laboratories Ltd is 10.0.